Name

Atezolizumab

Alternate Names

Anti-PD-L1 Monoclonal antibody MPDL3280A
RG7446
anti-PDL1
TECENTRIQ

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

monoclonal antibody

NSC Number

None

Primary Site

Bladder
Lung
Liver
Breast

Histology

Non small cell lung cancer (NSCLC), melanoma

Remarks

October 15, 2021 The FDA approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

July 30, 2020. The FDA approved atezolizumab (Tecentriq) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

June 5, 2020: Atezolizumab in combination with bevacizumab was approved by FDA for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

May 18, 2020 : The FDA approved atezolizumab (TECENTRIQ®) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations

December 3, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

March 18, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer.

12/6/2018 FDA approved atezolizumab (TECENTRIQ), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

7/20/2018: FDA has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as an initial treatment for people with advanced or metastatic hepatocellular.

4/23/2017: FDA granted accelerated approval to Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Tecentriq was previously approved for patients with locally advanced or mUC who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery or after surgery.

October 18, 2016: FDA approved atezolizumab (TECENTRIQ) for treatment of patients with metastatic non-small cell lung carcinoma (NSCLC)whose disease has progressed during or following platinum-containing chemotherapy.

May 18, 2016 FDA gave accelerated approval to atezolizumab injection (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Feb. 2015: FDA granted breakthrough designation to the immunotherapy MPDL3208A for patients with PD-L1 positive non-small cell lung cancer whose disease has progressed during or after platinum based chemotherapy and is an appropriate targeted therapy for those with an EGFR mutation-positive or ALK positive tumor.

2014: FDA granted breakthrough designation to MPDL3208A for treatment of bladder cancer.

Coding

This drug should be coded
Glossary